The TOMMORROW study was a landmark clinical research program that investigated whether an investigational medication could delay the onset of mild cognitive impairment, the earliest detectable stage of Alzheimer's disease, in cognitively healthy older adults. It was among the first organized efforts to intervene in Alzheimer's before symptoms begin, and its findings continue to shape prevention science worldwide. Tommorrow Study Collective was built to extend and amplify that mission.

The science says yes, and it's advancing rapidly. While no treatment has yet been approved to fully prevent Alzheimer's, a growing body of clinical research has identified genetic risk factors, lifestyle interventions, and investigational therapies that may delay or reduce the onset of symptoms. The TOMMORROW study was one of the first serious efforts to test this in cognitively healthy adults, and it represents the foundation of a larger prevention movement that is only gaining momentum.

Mild cognitive impairment is the earliest detectable stage of cognitive decline, a phase where changes in memory and thinking are noticeable but have not yet significantly disrupted daily life. MCI doesn't always progress to Alzheimer's, but it is widely recognized as a critical window for intervention. Much of the current prevention research, including the TOMMORROW study, focused on identifying and reaching people at this stage, or before it, to explore whether disease progression can be delayed.

Eligibility for Alzheimer's prevention trials varies by study and is determined by factors including age, cognitive health, genetic markers, and medical history. The best starting point is to speak with your primary care physician or a neurologist, who can assess your situation and refer you to appropriate research programs. You can also visit our Get Involved page to register your interest. Our team can help connect you with relevant research opportunities in your area.

No. Tommorrow Study Collective is an information and advocacy platform, not a medical provider. Our content is intended to educate, inform, and empower, not to diagnose, treat, or replace professional medical advice. If you have concerns about your cognitive health or are considering clinical trial participation, we strongly encourage you to consult a qualified healthcare provider. Everything we publish is grounded in peer-reviewed research and clinical evidence, but your doctor is your most important partner in any health decision.